Cystic fibrosis


Lung alert

Higher mortality from non-small cell lung cancer reported in subjects treated with oestrogen and progestin

The Women’s Health Initiative (WHI) trial was a double-blind randomised placebo-controlled trial that examined the health benefits and risks of combined oestrogen and progestin in 16 608 postmenopausal women in the USA. The study was stopped early as health risks were shown to exceed benefits. In this study, both incidence and mortality from lung cancer during the treatment and follow-up phases of the WHI (mean 7.9 years) were determined in a posthoc analysis.

No statistically significant differences in the incidence of lung cancer were seen between active (n=109) and placebo (n=85) groups (incidence 0.16% vs 0.13%; HR 1.23, 95% CI 0.92 to 1.65). More women died from lung cancer in the active (n=73) compared with the placebo (n=40) groups, and more deaths were seen in non-small cell lung cancer in the active (n=62; 0.09%) compared with the placebo (n=51; 0.08%) groups. There were no statistically significant differences in deaths from small cell lung cancer in the active (n=11; 0.02%) compared with the placebo (n=9; 0.01%) group.

Although there was no increase in the incidence of lung cancer in those on combined treatment, there was an increase in deaths attributable to lung cancer, especially in non-small cell disease. The authors speculate that combined hormone therapy stimulates growth of existing non-small cell lung cancers. This should be discussed with women considering combined hormone therapy, in particular those in a high-risk group.


P A Marsden

Correspondence to P A Marsden, ST3 Respiratory Medicine, Blackpool Victoria Hospital, UK;
P A.Marsden@manchester.ac.uk